SFS
ADAP

Sowell Financial Services’s Adaptimmune Therapeutics ADAP Stock Holding History

Sowell Financial Services’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-11,286
Closed -$61K – 3082
2020
Q4 		$61K Buy
11,286
+10,691
+1,797% +$58.1K ﹤0.01% 1321
2020
Q3 		$5K Hold
595
– – ﹤0.01% 1975
2020
Q2 		$6K Buy
+595
New +$3.74K ﹤0.01% 1827

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Sowell Financial Services's ADAP Position: Q1 2021 in Review

Sowell Financial Services sold out of Adaptimmune Therapeutics (ADAP) in Q1 2021, closing a stake of 11,286 shares — an estimated $61K sold.

Sowell Financial Services first reported a position in ADAP in Q2 2020 and held it in 3 quarters. The position peaked at $61K in Q4 2020. 84 funds tracked by Wall St. Rank hold ADAP as of Q1 2021.

  • Sowell Financial Services reported no remaining Adaptimmune Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Sowell Financial Services sold 11,286 Adaptimmune Therapeutics shares in Q1 2021, an estimated $61K.
  • Sowell Financial Services first reported a position in Adaptimmune Therapeutics in Q2 2020 and held it in 3 quarters.
  • Sowell Financial Services's Adaptimmune Therapeutics position peaked at $61K in Q4 2020.
  • 84 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q1 2021.

Based on Sowell Financial Services's 13F filing for Q1 2021, filed 7 May 2021.